Recent Updates
Recently added Catalysts

Posiphen

Phase 1

Alzheimer Disease | Small molecule | Neurology |Annovis Bio, Inc.|Last Updated: Feb 28, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment75
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04524351Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's PatientsPHASE1 COMPLETED 75Aug 14, 2020Jan 31, 2022Feb 28, 202313 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Treatment-Emergent Adverse Events
25±2 days

Percent of patients with AEs in the Posiphen treatment arms compared to the Placebo group

Secondary Endpoints
Concentration of Posiphen in Plasma
Samples collected over a 6 hour timeframe
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Posiphen, 80mg (Parkinson's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
Posiphen, 40mg (Parkinson's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
Posiphen, 20mg (Parkinson's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
Posiphen, 10mg (Parkinson's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
Posiphen, 5mg (Parkinson's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
Placebo (Parkinson's Participants)PLACEBO_COMPARATORPlacebo Oral Capsule, taken once per day for 25±2 days.
Placebo (Alzheimer's Participants)PLACEBO_COMPARATORPlacebo Oral Capsule, taken once per day for 25±2 days.
Posiphen, 80mg (Alzheimer's Participants)ACTIVE_COMPARATORPosiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
Interventions
NameTypeDescription
PosiphenDRUGSolid oral dosage form, capsule
PlaceboDRUGSolid oral dosage form, capsule
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria Subjects must meet the following criteria: 1. Male or female aged 45 years and over. 2. Female participants must be of non-childbearing potential or post-menopausal for at least 2 consecutive years or surgically sterile (bilateral tubal ligation, hysterectomy or bilateral oophor...

Countries:United States
Unlock Eligibility Criteria